酒精相关肝炎后再代偿与生存率提高相关:多中心研究结果
这项全国性注册研究纳入577例酒精相关肝炎出院患者(85%有肝硬化),评估再代偿率、预测因素及对生存的影响。1年和3年再代偿率按Baveno VII标准为9.9%和8.8%,按宽松戒酒标准为11.4%和14.3%。
要点
- 酒精相关肝炎后再代偿并不少见,尤其戒酒者1年再代偿率可达26.5%。
- 再代偿与长期无移植生存率提高独立相关,是长期生存的预测因素。
- 预测再代偿有助于临床决策,包括肝移植评估。
核心结论
- 酒精相关肝炎后再代偿较常见,尤其在戒酒患者中,且与生存率提高相关。
- 预测再代偿对临床决策(包括肝移植评估)有价值。
研究设计与样本
- 全国性注册研究,纳入2014年至2021年出院的酒精相关肝炎患者577例,85%有肝硬化。
- 再代偿分别按Baveno VII标准和酒精相关肝炎宽松戒酒标准定义,在1年和3年评估。
- 采用界标分析评估再代偿对无移植生存的影响。
主要发现
- 1年和3年再代偿率:Baveno VII标准为9.9%和8.8%,宽松戒酒标准为11.4%和14.3%。
- 肝硬化患者1年和3年再代偿率(Baveno VII)为8.2%和9.0%。
- 1年时戒酒者1年和3年再代偿率分别为26.5%和25.8%。
- 再代偿者5年无移植生存率84.9%,未代偿者47.7%(Plog-rank < .001)。
- 酒精相关肝炎前无失代偿、基线碱性磷酸酶较高和Child-Pugh评分较低与再代偿独立相关。
关键数值与推荐
- 再代偿定义采用Baveno VII标准或酒精相关肝炎宽松戒酒标准(不要求戒酒)。
- 再代偿是长期生存的预测因素。
临床怎么用
- 临床可评估酒精相关肝炎患者的再代偿预测因素,辅助判断预后和肝移植需求。
- 戒酒与再代偿率提高相关,应强调戒酒管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The rate of recompensation following alcohol-related hepatitis is unknown. The aims of this study were to assess the rate, predictors, and clinical impact of recompensation in survivors of alcohol-related hepatitis, and to develop adapted recompensation criteria. METHODS: Nationwide registry-based study including patients with alcohol-related hepatitis who were discharged between 2014 and 2021. Recompensation was defined according to: (1) Baveno VII criteria; or (2) expanded criteria for alcohol-related hepatitis in which alcohol abstinence was not required (alcohol-related hepatitis liberal-abstinence criteria); and was assessed at 1 and 3 years. A landmark analysis was used to evaluate the impact of recompensation on transplant-free survival. RESULTS: A total of 577 patients (85% with cirrhosis) were included. The rate of recompensation at 1 and 3 years was 9.9% and 8.8% (Baveno VII), and 11.4% and 14.3% (alcohol-related hepatitis liberal-abstinence). In patients with cirrhosis, rates were 8.2% and 9.0% at 1 and 3 years (Baveno VII). The absence of decompensation prior to alcohol-related hepatitis, higher baseline alkaline phosphatase levels and lower Child-Pugh score were independently associated with recompensation. In patients abstinent from alcohol at 1 year, the rate of recompensation at 1 and 3 years was 26.5% and 25.8%, respectively. Patients with recompensated disease had higher estimated 5-year transplant-free survival (84.9% vs 47.7% in decompensated disease; Plog-rank < .001). Survival estimates did not differ when classifying patients according to alcohol-related hepatitis liberal-abstinence criteria. Recompensation after alcohol-related hepatitis was a predictor of long-term survival. CONCLUSIONS: Recompensation in alcohol-related hepatitis is common, particularly following abstinence, and is associated with increased survival. Predicting recompensation in alcohol-related hepatitis can be valuable in decision-making, including the evaluation for liver transplantation.
引用
- Gratacós-Ginès J, Ruz-Zafra P, Herms Q, et al. Recompensation Following Alcohol-Related Hepatitis Is Associated With Increased Survival: Results From a Multicenter Study. Clin Gastroenterol Hepatol. 2026. PMID: 42242660. doi:10.1016/j.cgh.2026.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。